Nakamura Mami, Miyazaki Ayako, Takubo Takayuki, Matsuzawa Yoko, Saito Jun, Omura Masao, Nishikawa Tetsuo
Department of Medicine, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama City, 222-0036, Japan.
Jpn Clin Med. 2011 Feb 2;2:1-7. doi: 10.4137/JCM.S5971. Print 2011.
Hemoglobin A1c (HbA1c) is an important parameter for evaluating long-term (6-8 weeks) control of blood glucose levels in patients with diabetes mellitus. We report a Japanese diabetic case who harbored abnormal Hb and demonstrated falsely low HbA1c levels in the regular ion exchange HPLC-based assay. His abnormal β-globin chain had an amino acid replacement that corresponded to glycine to serine substitution at amino acid position 136 of the β-globin chain (Hb Perpignan). Accordingly, a heterozygotic point mutation replacing guanine by adenine at nucleotide position 406 (β136G > S) was identified in the β-globin gene of the proband and his son. These results indicate that the patient had Hb Perpignan, and this abnormal Hb interfered with the HPLC-based HbA1c assay commonly used in the clinic. The cases presented are the first report of patients in the Japanese population harboring Hb Perpignan (β136G > S).
糖化血红蛋白(HbA1c)是评估糖尿病患者血糖水平长期(6 - 8周)控制情况的重要参数。我们报告了一例日本糖尿病患者,其血红蛋白(Hb)异常,在基于离子交换高效液相色谱法(HPLC)的常规检测中显示HbA1c水平假性降低。他的异常β珠蛋白链存在氨基酸替换,相当于β珠蛋白链第136位氨基酸由甘氨酸替换为丝氨酸(佩皮尼昂血红蛋白,Hb Perpignan)。因此,在该先证者及其儿子的β珠蛋白基因中鉴定出一个杂合子点突变,即第406位核苷酸处腺嘌呤取代鸟嘌呤(β136G > S)。这些结果表明该患者患有佩皮尼昂血红蛋白,这种异常Hb干扰了临床常用的基于HPLC的HbA1c检测。本文报道的病例是日本人群中携带佩皮尼昂血红蛋白(β136G > S)患者的首例报告。